The Effect of Survival, Response and Microbiota Change in Different Therapy Under Probiotic Supplement

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorChang Gung Memorial Hospital

About this trial

Probiotics are a group of viable microorganisms including bacteria and yeasts that if consumed in sufficient amounts, may afford health benefits to the host. The major advantage of probiotic administration is its ability to maintain gut microbial homeostasis, reduce pathogenic microorganisms in the GI tract, and restores homeostasis of intestinal microorganisms. Moreover, by modulating microbiota and immune responses, decreasing bacterial translocation, promoting the function of the gut barrier, inducing anti- inflammatory properties, triggering anti-pathogenic activity, and decreasing tumor development and metastasis, probiotics might contribute to the prevention and treatment of GI cancers and lung cancer. Considering the potential roles of Helicobacter pylori (H. pylori) in the initiation of colorectal and gastric cancers, the possible properties of probiotics against GI neoplasm in humans have been investigated in relation to their suppressive effects on H. pylori. The gut microbiota also has proved to in the response and resistance to immunotherapy. By triggering immune activity, probiotics, as functional dietary supplements, may mitigate neoplastic predisposition and development of GI cancers. Clostridium butyricum is a spore-forming bacillus named for its capacity to produce high amounts of butyric acid and is found in soil. Clostridium butyricum MIYAIRI 588 strain (MIYA-BM) is widely used as probiotic therapy to improve symptoms related to dysbiosis such as constipation, nonantimicrobial diarrhea, and anti- microbial-associated diarrhea in Japan and China. Clostridium butyricum increases beneficial bacteria, especially lactobacilli and bifidobacteria. Bifidobacterium promotes antitumor immunity and facilitates efficacy of antitumor treatment. The antitumor treatments are differed to three types: immune checkpoint blockade, target therapy and chemotherapy. Thus, investigators hypothesized that probiotic Clostridium butyricum therapy (CBT) may enhance the therapeutic efficacy of anti-tumor therapy through the modulation of gut microbiota. Investigators will discuss the different kinds of anti-tumor effect in survival and response after probiotic supplement.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

age≧20

participants with cancer therapy and agree to sign informed consent

Cancer confirmed by clinical or pathological diagnosis

Disqualifiers

age<20

Pregnant or breastfeeding women

Trial design

Design model

Parallel

Treatments tested in this trial

  • Probiotics

    Combination product

    Participants will intake 90days Probiotics

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: controlNo intervention 0 interventions
Group B: experimentalExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

phenoage score

collect 10 mL of peripheral blood, and caculate the phenoage

Time frame
baseline
2

phenoage score

collect 10 mL of peripheral blood, and caculate the phenoage

Time frame
3 month
3

Metagenomic shotgun sequencing

Collect stool samples to analyze the types and unique characteristics of microorganisms

Time frame
baseline
4

Metagenomic shotgun sequencing

Collect stool samples to analyze the types and unique characteristics of microorganisms

Time frame
3 month

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.